ArticleThe Journal of experimental medicine1996
Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Applying a clinical lens to animal models of CAR-T cell therapies.Molecular therapy. Methods & clinical development · 2022Review
- Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine.Molecular therapy. Methods & clinical development · 2022Article
- Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques.JCI insight · 2021Article
- CARs: Beyond T Cells and T Cell-Derived Signaling Domains.International journal of molecular sciences · 2020Review
- Chimeric antigen receptor T-cell approaches to HIV cure.Current opinion in HIV and AIDS · 2018Review
- Quarter Century of Anti-HIV CAR T Cells.Current HIV/AIDS reports · 2018Review
- Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.Human vaccines & immunotherapeutics · 2017Article
- Article
- A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.Oncotarget · 2016Article
- HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Hematopoietic stem cells for cancer immunotherapy.Immunological reviews · 2014Review
- Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.Human gene therapy · 2013Article
- T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.Gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene modification of hematopoietic stem cells (HSC) with antigen-specific, chimeric, or "universal" immune receptors (URs) is a novel but untested form of targeted immunotherapy. A human immunodeficiency virus (HIV) envelope-specific UR consisting of the extracellular domain of human CD4 linked to the zeta chain of the T cell receptor (CD4 zeta) was introduced ex vivo into murine HSC by retroviral transduction. After transplantation into immunodeficient SCID mice, sustained high level expression of CD4 zeta was observed in circulating myeloid and natural killer cells. CD4 zeta-transplanted mice were protected from challenge with a lethal dose of a disseminated human leukemia expressing HIV envelope. These results demonstrate the ability of chimeric receptors bearing zeta-signaling domains to activate non-T cell effector populations in vivo and thereby mediate systemic immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.